Evidence map›Paper›PMID 33666138›Full record

ArticleExpert review of vaccines2021

Immunization and Drug Metabolizing Enzymes: Focus on Hepatic Cytochrome P450 3A.

Kristina Jonsson-Schmunk, Romi Ghose, Maria A Croyle

Open access · greenAbstract read
In one paragraph

Article in Expert review of vaccines, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
0.4field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 8 citations in OpenAlex.

  1. Pooled it
  2. Assessment ofMolecular pharmaceutics · 2025
    Article
  3. Article
  4. Article
  5. Role of Cytochrome P450 2C9 in COVID-19 Treatment: Current Status and Future Directions.European journal of drug metabolism and pharmacokinetics · 2023
    Review
  6. COVID-19 Vaccines and the Virus: Impact on Drug Metabolism and Pharmacokinetics.Drug metabolism and disposition: the biological fate of chemicals · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Kristina Jonsson-SchmunkMolecular Pharmaceutics and Drug Delivery, College of Pharmacy, The University of Texas, Austin, Texas, USA.
Romi GhoseDepartment of Pharmacological and Pharmaceutical Sciences, College of Pharmacy, University of Houston, Houston, Texas, USA.
Maria A CroyleMolecular Pharmaceutics and Drug Delivery, College of Pharmacy, The University of Texas, Austin, Texas, USA.
The University of Texas at Austin · USUniversity of Houston · US

Funding

Evaluation of Protective Immunity After Mucosal Vaccination Against Ebola VirusU01AI078045 · NIAID · UNIVERSITY OF TEXAS AT AUSTIN · PI CROYLE, MARIA A · 2008 to 2012
$2.5M
NIAID NIH HHS U01 AI078045
6 · The paper itself

Abstract

objectiveInfectious disease emergencies like the 2013-2016 Ebola epidemic and the 2009 influenza and current SARS-CoV-2 pandemics illustrate that vaccines are now given to diverse populations with preexisting pathologies requiring pharmacological management. Many natural biomolecules (steroid hormones, fatty acids, vitamins) and ~60% of prescribed medications are processed by hepatic cytochrome P450 (CYP) 3A4. The objective of this work was to determine the impact of infection and vaccines on drug metabolism.

methodsThe impact of an adenovirus-based vaccine expressing Ebola glycoprotein (AdEBO) and H1N1 and H3N2 influenza viruses on hepatic CYP 3A4 and associated nuclear receptors was evaluated in human hepatocytes (HC-04 cells) and in mice.

resultsCYP3A activity was suppressed by 55% in mice 24 h after administration of mouse-adapted H1N1, while ˂10% activity remained in HC-04 cells after infection with H1N1 and H3N2 due to global suppression of cellular translation capacity, indicated by reduction (70%, H1N1, 56%, H3N2) of phosphorylated eukaryotic translation initiation factor 4e (eIF4E). AdEBO suppressed CYP3A activity

conclusionAs the clinical evaluation of vaccines for SARS-CoV-2 and other global pathogens rise, studies to evaluate the impact of new vaccines and emerging pathogens on CYP3A4 and other metabolic enzymes are warranted to avoid therapeutic failures that could further compromise the public health during infectious disease emergencies.

Indexed as

AnimalsCells, CulturedCytochrome P-450 CYP3AEukaryotic Initiation Factor-4EHepatocytesHumansImmunizationLiverMaleMiceMice, Inbred BALB CMice, Inbred C57BLPharmaceutical PreparationsCytochrome P-450 CYP3AEukaryotic Initiation Factor-4EPharmaceutical PreparationsCytochrome P450 3A4drug metabolismebolainfluenzalivervaccine

Identifiers

PMID33666138
PMCPMC8292194
OpenAlexW3135881959

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.